/

SLXN

Silexion Therapeutics CorpPre-market

0.1760−0.00 −1.23%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 0.1856 +5.45%

Open

0.1880

Prev close

0.1782

Day range

0.16300.1934

52-week range

0.163038.20

Volume

2.04M0.20×

Mkt cap

2.55M

P/E ttm

—

Fwd P/E

-0.28

EPS ttm

-27.21

Div yield

0.00%

Earnings

—

From 52w high

−99.54%

Price Chart

Yahoo Finance · delayed

SLXNOct 13, 2026O 0.1880H 0.1940L 0.1630C 0.1760−0.0020 (−1.12%)Vol 2.06M

SMA 500.4995
SMA 2008.0227

1Y change −99.53% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SLXN Silexion Therapeutics Corp · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −33.08%
1 month: −50.70%
3 months: −92.96%
6 months: −98.31%
Year to date: −99.08%
1 year: −99.53%

Valuation & ownership

Market cap: 2.55M
Enterprise value: 159.60K
P/E (ttm): —
Forward P/E: -0.28
PEG ratio: —
Price / book: 22.00
Price / sales (ttm): —
EV / EBITDA: -0.01
EPS (ttm): -27.21
EPS (forward): -0.6400
Beta (5y monthly): -0.30
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 14.47M
Float: 5.56M
Short % of float: 34.47%
Short ratio (days): 0.18
Held by insiders: 14.67%
Held by institutions: 0.32%
Avg volume (3m): 10.08M
50-day average: 0.5350
200-day average: 8.14
52-week change: −99.53%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.6
vs 50-day SMA: −64.76%
vs 200-day SMA: −97.81%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 35.51%
Realised vol (20d, ann.): 228.9%
From 52-week high: −99.54%
From 52-week low: +7.98%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

5.00

+2,740.91% implied

Low 5.00Median 5.00High 5.00

Recommendation trend

Now1 / 1 / 0
1m ago1 / 1 / 0
2m ago

DES

About Silexion Therapeutics Corp

Yahoo Finance profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 13
Headquarters: Jerusalem, Israel
Website: silexion.com
Officers: Mr. Ilan Hadar M.B.A. Chairman & CEO
Ms. Mirit Horenshtein Hadar EVP of Finance Affairs, CFO & Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D. Chief Scientific & Development Officer

SEAS

Seasonality · SLXN

2021–2026 · monthly returns

Strongest month Nov +166.27%Weakest month Aug −27.75%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.7	-5.7	-25.8	-52.2	-19.8	-48.1	-26.3	-80.3	-25.1	-36.5			−99.1%
2025	-5.5	-43.7	2.8	-10.5	5.6	-22.1	23.0	-51.0	-53.6	-2.5	-14.6	-32.2	−93.6%
2024	1.2	0.6	1.5	1.0	1.1	2.6	2.1	-87.8	-64.0	-43.8	845.8	-28.0	−81.5%
2023	0.8	0.1	1.2	0.1	0.5	1.8	1.1	1.0	1.1	-0.2	0.0	0.0	+7.7%
2022	0.0	0.6	0.4	0.5	0.0	-0.1	0.2	0.5	0.4	0.5	0.4	0.5	+4.0%
2021					-0.9	0.0	1.5	-1.4	0.5	0.4	-0.2	-0.4	−0.6%

INSD

Insider Activity · SLXN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

686.7K shares

Sells, 6 months

22.8K shares

Net shares

+663.8K

Net change in insider shares

+436.60%

Date	Insider	Transaction	Shares	Value
Jun 3, 2026	Shirvan MitchellOfficer	Stock Award(Grant) at price 0.00 per share.	6K	—
Jun 3, 2026	Hadar IlanChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 3, 2026	Horenshtein Hadar MiritChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Mar 25, 2026	Shirvan MitchellOfficer	Sale at price 1.36 per share.	22.8K	$31.03K
Feb 19, 2026	Shirvan MitchellOfficer	Stock Award(Grant) at price 0.00 per share.	49.7K	—
Feb 19, 2026	Hadar IlanChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	64.3K	—
Feb 19, 2026	Alon RuthDirector	Stock Award(Grant) at price 0.00 per share.	9.1K	—
Feb 19, 2026	Horenshtein Hadar MiritChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	49.7K	—
Feb 19, 2026	Lushi AvnerDirector	Stock Award(Grant) at price 0.00 per share.	9.1K	—
Feb 19, 2026	Abramov Dror YosefDirector	Stock Award(Grant) at price 0.00 per share.	9.1K	—
Feb 19, 2026	Noy ShlomoDirector	Stock Award(Grant) at price 0.00 per share.	9.1K	—
Feb 19, 2026	Peled Amnon Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	7.6K	—
Sep 14, 2025	Levin IlanDirector and Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 4.00 per share.	450K	$1.80M
Feb 6, 2025	Alon RuthDirector	Stock Award(Grant) at price 0.00 per share.	794	—
Feb 6, 2025	Lushi AvnerDirector	Stock Award(Grant) at price 0.00 per share.	1.6K	—
Feb 6, 2025	Abramov Dror YosefDirector	Stock Award(Grant) at price 0.00 per share.	794	—
Feb 6, 2025	Noy ShlomoDirector	Stock Award(Grant) at price 0.00 per share.	1.6K	—
Feb 6, 2025	Peled Amnon Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	661	—

SLXN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SLXN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Silexion Therapeutics Corp

Seasonality · SLXN

Insider Activity · SLXN

Congress Trades · SLXN

Investors Holding SLXN

Investors Holding SLXN

Congress Trades · SLXN

Insider Activity · SLXN

Seasonality · SLXN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Silexion Therapeutics Corp

Financial Snapshot

Earnings & Dividends

News